EUCTR2004-000299-15-SE进行中（未招募）1 期
A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
Algeta AS0 个研究点目标入组 0 人开始时间: 2004年7月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Histologically/cytologically confirmed adenocarcinoma of the prostate
- •2. Patient is hormone refractory with evidence of progressive disease:
- •- Patient must be maintained on androgen ablation therapy with LHRH agonist, or is currently treated with polyestradiolphosphate to castrate level, or have undergone orchiectomy
- •- Patient’s testosterone level is required to be equal to or below 50 ng/dl
- •- Patients in which flutamide, nilutamide, megestrol acetate, polyestradiolphosphate, aminoglutethimide, and ketoconazole, has been recently added or withdrawn must demonstrate progression of disease and be at least 4 weeks beyond the start or discontinuation of such agents; for bicalutamide 6 weeks is required
- •- Increase in PSA levels in two consecutive measurements with at least one week apart, demonstrating an increase over the reference (nadir) value, and with the final PSA > 5 ng/ml
- •o A reference PSA (nadir) value must be measured at least 4 weeks after the start or discontinuation of flutamide, nilutamide, megestrol acetate, polyestradiolphosphate, aminoglutethimide, and ketoconazole, and at least 6 weeks after start or discontinuation of bicalutamide
- •o If the third PSA value is lower than the second value, the patient could still be eligible, provided a fourth measurement obtained at least 1 week after the third PSA value, is greater than the second PSA value and > 5 ng/ml
- •3. Multifocal (>1) skeletal metastases confirmed by bone scintigraphy within the last 6 weeks
- •4. Bone pain with a score of at least 2 on BPI average pain, despite adequate use of analgesics, that correlates with areas of increased uptake (osteoblastic activity) on bone scintigraphy
- •5. Performance status: ECOG 0-2 or Karnofsky ³ 60%
- •6. Life expectancy: At least 3 months
- •7. Age more than 40 years
- •8. Laboratory requirements:
- •a. Neutrophil count > 1,5 x 109/L
- •b. Platelet count at least > 100 x109/L
- •c. Hemoglobin > 95 g/L
- •d. Bilirubin within normal institutional limits
- •e. ASAT and ALAT < 2,5 times upper limit of normal (ULN)
- •9. The patient is willing and able to comply with the protocol (including maintenance of patient diary and completion of pain assessment forms), and agrees to return to the hospital for follow-up visits and examination
- •10. The patient has been fully informed about the study and has signed the informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has received an investigational drug within 4 weeks before the administration of radium-223, or is scheduled to receiving one during the study period
- •2. Has received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •3. Has received prior hemibody external radiotherapy
- •4. Has received systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last year prior to inclusion
- •5. Has started treatment with bisphosphonates less than 3 months prior to administration of study drug
- •6. Patients experiencing hormone withdrawal syndrome, or are < 4 weeks post withdrawal of antiandrogen therapy (6 weeks for bicalutamide)
- •7. Patients who have started steroids or changed to treatment with steroids within the last 4 weeks prior to administration of radium-223
- •8. Has other clinically significant or symptomatic disease, which might interfere with the assessment of bone pain, e.g. spinal cord compression, compression or infiltration of a neural plexus, nerve root or peripheral nerves
- •9. Other currently active (relapse within the last 3 year) malignancy (except non-melanoma skin cancer), or known brain or visceral metastases dominating the clinical picture of the patient
- •10. Other serious illness or medical condition:
- •- any uncontrolled infection
- •- cardiac failure Classification III or IV (New York Heart Association)
- •- Crohn disease or Ulcerative colitis
- •- known bone fracture within 8 weeks
- •11. Patients with imminent or established spinal cord compression based on clinical findings and/or MRI
研究者
相似试验
进行中（未招募）
1 期
A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients. - Not applicablePatients with painful bone metastases secondary to prostate carcinoma.EUCTR2004-000299-15-GBAlgeta ASA, Oslo, Norway
进行中（未招募）
1 期
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer’s DiseaseAlzheimer's DiseaseCTIS2023-509613-37-01Amsterdam UMC40
进行中（未招募）
1 期
Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD-4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary DiseaseEUCTR2012-004949-32-DETheravance, Inc.62
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants with Cognitive Impairment Associated with Schizophrenia (CIAS)SchizophreniaEUCTR2018-003825-27-GBBiogen Idec Research Limited219
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants with Cognitive Impairment Associated with Schizophrenia (CIAS)MedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2018-003825-27-DEBiogen Idec Research Limited219